Document is current
Any future updates will be listed below
-
Authors
Özbay Kurt, Feyza Gül https://orcid.org/0000-0003-4086-6469
Cicortas, Beatrice-Ana
Balzasch, Bianca M
De la Torre, Carolina
Ast, Volker
Tavukcuoglu, Ece
Ak, Cagla
Wohlfeil, Sebastian A
Cerwenka, Adelheid
Utikal, Jochen
Umansky, Viktor https://orcid.org/0000-0003-0259-1839
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04405167 at ClinicalTrials.govDocuments that mention this clinical trial
Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma
https://doi.org/10.1136/jitc-2022-005319
Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM).
https://doi.org/10.1200/jco.2023.41.16_suppl.8042
S100A9 and HMGB1 orchestrate MDSC-mediated immunosuppression in melanoma through TLR4 signaling
https://doi.org/10.1136/jitc-2024-009552
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (74114180)
Bundesministerium für Bildung und Forschung (01KU2017)
Deutsche Forschungsgemeinschaft (259332240/RTG2099)
Deutsche Forschungsgemeinschaft (445549683/RTG2727)
German Academic Exchange Service (57516591)
- License Information
